The CD95/CD95L signaling pathway: A role in carcinogenesis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 130-141

  Fouqué, Amélie ^a,b,c,d   Debure, Laure ^a,b,c,d   Legembre, Patrick ^a,b,c,d  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Equipe Labellisée Ligue Contre Le Cancer Death Receptors and Tumor Escape   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

Author keywords

Apoptosis; Carcinogenesis; Cytokine; Fas; Inflammation

Indexed keywords

CALCIUM ION; FAS ANTIGEN; FAS LIGAND; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; HLA DR6 ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN FUNCTION; APOPTOSIS; BREAST CANCER; CARCINOGENESIS; CD95 GENE; COLON CANCER; GENE FUNCTION; GENE MUTATION; HUMAN; INTERNALIZATION; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LIPID RAFT; MALIGNANT NEOPLASTIC DISEASE; NECROPTOSIS; NK T CELL LYMPHOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; CALCIUM TRANSPORT; DISEASE ACTIVITY; DISEASE ASSOCIATION; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN STRUCTURE;

APOPTOSIS; CARCINOGENESIS; CYTOKINE; FAS; INFLAMMATION;

ANIMALS; ANTIGENS, CD95; CARCINOGENESIS; FAS LIGAND PROTEIN; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 84901442328     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.04.007     Document Type: Review

References (186)

1. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell 1996, 87:171.
2. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
3. Boldin M.P., Varfolomeev E.E., Pancer Z., Mett I.L., Camonis J.H., Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 1995, 270:7795-7798.
4. Chinnaiyan A.M., O'Rourke K., Tewari M., Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
5. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995, 81:495-504.
6. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995, 14:5579-5588.
7. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
8. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
9. Loetscher H., Pan Y.C., Lahm H.W., Gentz R., Brockhaus M., Tabuchi H., Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990, 61:351-359.
10. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
11. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., Timour M.S., Gerhart M.J., Schooley K.A., Smith C.A., Goodwin R.G., Rauch C.T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997, 16:5386-5397.
12. Pan G., Bauer J.H., Haridas V., Wang S., Liu D., Yu G., Vincenz C., Aggarwal B.B., Ni J., Dixit V.M. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 1998, 431:351-356.
13. Alderson M.R., Armitage R.J., Maraskovsky E., Tough T.W., Roux E., Schooley K., Ramsdell F., Lynch D.H. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 1993, 178:2231-2235.
14. Schulze-Osthoff K., Krammer P.H., Droge W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J. 1994, 13:4587-4596.
15. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959-962.
16. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
17. Bodmer J.L., Schneider P., Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 2002, 27:19-26.
18. Edmond V., Ghali B., Penna A., Taupin J.L., Daburon S., Moreau J.F., Legembre P. Precise mapping of the CD95 pre-ligand assembly domain. PLoS ONE 2012, 7:e46236.
19. Papoff G., Hausler P., Eramo A., Pagano M.G., Di Leve G., Signore A., Ruberti G. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J. Biol. Chem. 1999, 274:38241-38250.
20. Siegel R.M., Frederiksen J.K., Zacharias D.A., Chan F.K., Johnson M., Lynch D., Tsien R.Y., Lenardo M.J. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000, 288:2354-2357.
21. Itoh N., Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J. Biol. Chem. 1993, 268:10932-10937.
22. Tartaglia L.A., Ayres T.M., Wong G.H., Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74:845-853.
23. Tang W., Lu Y., Tian Q.Y., Zhang Y., Guo F.J., Liu G.Y., Syed N.M., Lai Y., Lin E.A., Kong L., Su J., Yin F., Ding A.H., Zanin-Zhorov A., Dustin M.L., Tao J., Craft J., Yin Z., Feng J.Q., Abramson S.B., Yu X.P., Liu C.J. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011, 332:478-484.
24. Cabal-Hierro L., Lazo P.S. Signal transduction by tumor necrosis factor receptors. Cell. Signal. 2012, 24:1297-1305.
25. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
26. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel D.V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312:724-729.
27. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
28. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., Chen W.J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R., Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F., Seaton T., Su J.L., Becherer J.D., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
29. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
30. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
31. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
32. Haas T.L., Emmerich C.H., Gerlach B., Schmukle A.C., Cordier S.M., Rieser E., Feltham R., Vince J., Warnken U., Wenger T., Koschny R., Komander D., Silke J., Walczak H. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 2009, 36:831-844.
33. Kirisako T., Kamei K., Murata S., Kato M., Fukumoto H., Kanie M., Sano S., Tokunaga F., Tanaka K., Iwai K. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 2006, 25:4877-4887.
34. Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E., Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W., Nachbur U., Gangoda L., Warnken U., Purcell A.W., Silke J., Walczak H. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011, 471:591-596.
35. Poukkula M., Kaunisto A., Hietakangas V., Denessiouk K., Katajamaki T., Johnson M.S., Sistonen L., Eriksson J.E. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J. Biol. Chem. 2005, 280:27345-27355.
36. Enesa K., Zakkar M., Chaudhury H., Luong le A., Rawlinson L., Mason J.C., Haskard D.O., Dean J.L., Evans P.C., Evans P.C. NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J. Biol. Chem. 2008, 283:7036-7045.
37. Green D.R., Oberst A., Dillon C.P., Weinlich R., Salvesen G.S. RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. Mol. Cell 2011, 44:9-16.
38. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J.L., Schneider P., Seed B., Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 2000, 1:489-495.
39. Vercammen D., Beyaert R., Denecker G., Goossens V., Van Loo G., Declercq W., Grooten J., Fiers W., Vandenabeele P. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 1998, 187:1477-1485.
40. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., Chan F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
41. Kaiser W.J., Upton J.W., Long A.B., Livingston-Rosanoff D., Daley-Bauer L.P., Hakem R., Caspary T., Mocarski E.S. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011, 471:368-372.
42. Oberst A., Dillon C.P., Weinlich R., McCormick L.L., Fitzgerald P., Pop C., Hakem R., Salvesen G.S., Green D.R. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
43. Welz P.S., Wullaert A., Vlantis K., Kondylis V., Fernandez-Majada V., Ermolaeva M., Kirsch P., Sterner-Kock A., van Loo G., Pasparakis M. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011, 477:330-334.
44. Feldmann M., Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 2003, 9:1245-1250.
45. Desbarats J., Birge R.B., Mimouni-Rongy M., Weinstein D.E., Palerme J.S., Newell M.K. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 2003, 5:118-125.
46. Desbarats J., Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 2000, 6:920-923.
47. Letellier E., Kumar S., Sancho-Martinez I., Krauth S., Funke-Kaiser A., Laudenklos S., Konecki K., Klussmann S., Corsini N.S., Kleber S., Drost N., Neumann A., Levi-Strauss M., Brors B., Gretz N., Edler L., Fischer C., Hill O., Thiemann M., Biglari B., Karray S., Martin-Villalba A. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010, 32:240-252.
48. O' Reilly L.A., Tai L., Lee L., Kruse E.A., Grabow S., Fairlie W.D., Haynes N.M., Tarlinton D.M., Zhang J.G., Belz G.T., Smyth M.J., Bouillet P., Robb L., Strasser A. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461:659-663.
49. Ruan W., Lee C.T., Desbarats J. A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth. Mol. Biol. Cell 2008, 19:3192-3202.
50. Tauzin S., Chaigne-Delalande B., Selva E., Khadra N., Daburon S., Contin-Bordes C., Blanco P., Le Seyec J., Ducret T., Counillon L., Moreau J.F., Hofman P., Vacher P., Legembre P. The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol. 2011, 9:e1001090.
51. Tauzin S., Debure L., Moreau J.F., Legembre P. CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cell. Mol. Life Sci. 2012, 69:1261-1277.
52. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305.
53. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
54. Oshimi Y., Oda S., Honda Y., Nagata S., Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol. 1996, 157:2909-2915.
55. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192.
56. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection. Nature 1995, 377:630-632.
57. Behrmann I., Walczak H., Krammer P.H. Structure of the human APO-1 gene. Eur. J. Immunol. 1994, 24:3057-3062.
58. Lang I., Fick A., Schafer V., Giner T., Siegmund D., Wajant H. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts. J. Biol. Chem. 2012, 287:24026-24042.
59. Huang B., Eberstadt M., Olejniczak E.T., Meadows R.P., Fesik S.W. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996, 384:638-641.
60. Scott F.L., Stec B., Pop C., Dobaczewska M.K., Lee J.J., Monosov E., Robinson H., Salvesen G.S., Schwarzenbacher R., Riedl S.J. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009, 457:1019-1022.
61. Esposito D., Sankar A., Morgner N., Robinson C.V., Rittinger K., Driscoll P.C. Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C terminus. Structure 2010, 18:1378-1390.
62. Wang L., Yang J.K., Kabaleeswaran V., Rice A.J., Cruz A.C., Park A.Y., Yin Q., Damko E., Jang S.B., Raunser S., Robinson C.V., Siegel R.M., Walz T., Wu H. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct. Mol. Biol. 2010, 17:1324-1329.
63. Muppidi J.R., Lobito A.A., Ramaswamy M., Yang J.K., Wang L., Wu H., Siegel R.M. Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis. Cell Death Differ. 2006, 13:1641-1650.
64. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
65. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.L., Schroter M., Scaffidi C., Krammer P.H., Peter M.E., Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
66. Condorelli G., Vigliotta G., Cafieri A., Trencia A., Andalo P., Oriente F., Miele C., Caruso M., Formisano P., Beguinot F. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999, 18:4409-4415.
67. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17:1675-1687.
68. Algeciras-Schimnich A., Pietras E.M., Barnhart B.C., Legembre P., Vijayan S., Holbeck S.L., Peter M.E. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11445-11450.
69. Chaigne-Delalande B., Mahfouf W., Daburon S., Moreau J.F., Legembre P. CD95 engagement mediates actin-independent and -dependent apoptotic signals. Cell Death Differ. 2009, 16:1654-1664.
70. Yin X.M. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 2000, 10:161-167.
71. Yin X.M., Wang K., Gross A., Zhao Y., Zinkel S., Klocke B., Roth K.A., Korsmeyer S.J. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999, 400:886-891.
72. Jost P.J., Grabow S., Gray D., McKenzie M.D., Nachbur U., Huang D.C., Bouillet P., Thomas H.E., Borner C., Silke J., Strasser A., Kaufmann T. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009, 460:1035-1039.
73. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997, 16:6914-6925.
74. Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
75. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
76. Suzuki Y., Nakabayashi Y., Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8662-8667.
77. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
78. Sun X.M., Bratton S.B., Butterworth M., MacFarlane M., Cohen G.M. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J. Biol. Chem. 2002, 277:11345-11351.
79. Beneteau M., Pizon M., Chaigne-Delalande B., Daburon S., Moreau P., De Giorgi F., Ichas F., Rebillard A., Dimanche-Boitrel M.T., Taupin J.L., Moreau J.F., Legembre P. Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway. Mol. Cancer Res. 2008, 6:604-613.
80. Peacock J.W., Palmer J., Fink D., Ip S., Pietras E.M., Mui A.L., Chung S.W., Gleave M.E., Cox M.E., Parsons R., Peter M.E., Ong C.J. PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Mol. Cell. Biol. 2009, 29:1222-1234.
81. Varadhachary A.S., Edidin M., Hanlon A.M., Peter M.E., Krammer P.H., Salgame P. Phosphatidylinositol 3'-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95. J. Immunol. 2001, 166:6564-6569.
82. Pizon M., Rampanarivo H., Tauzin S., Chaigne-Delalande B., Daburon S., Castroviejo M., Moreau P., Moreau J.F., Legembre P. Actin-independent exclusion of CD95 by PI3K/AKT signalling: implications for apoptosis. Eur. J. Immunol. 2011, 41:2368-2378.
83. Renganathan H., Vaidyanathan H., Knapinska A., Ramos J.W. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Biochem. J. 2005, 390:729-735.
84. Trencia A., Perfetti A., Cassese A., Vigliotta G., Miele C., Oriente F., Santopietro S., Giacco F., Condorelli G., Formisano P., Beguinot F. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol. Cell. Biol. 2003, 23:4511-4521.
85. Strasser A., Harris A.W., Huang D.C., Krammer P.H., Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995, 14:6136-6147.
86. Lacronique V., Mignon A., Fabre M., Viollet B., Rouquet N., Molina T., Porteu A., Henrion A., Bouscary D., Varlet P., Joulin V., Kahn A. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 1996, 2:80-86.
87. Rodriguez I., Matsuura K., Khatib K., Reed J.C., Nagata S., Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J. Exp. Med. 1996, 183:1031-1036.
88. Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.L., Elkon K.B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 1996, 335:1643-1649.
89. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., Strober W., Lenardo M.J., Puck J.M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946.
90. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A., Debatin K.M., Fischer A., de Villartay J.P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349.
91. Canale V.C., Smith C.H. Chronic lymphadenopathy simulating malignant lymphoma. J. Pediatr. 1967, 70:891-899.
92. Rieux-Laucat F., Blachere S., Danielan S., De Villartay J.P., Oleastro M., Solary E., Bader-Meunier B., Arkwright P., Pondare C., Bernaudin F., Chapel H., Nielsen S., Berrah M., Fischer A., Le Deist F. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations. Blood 1999, 94:2575-2582.
93. Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B., Rosen-Wolff A., Peters A.M., Sneller M.C., Hallahan C.W., Wang J., Fischer R.E., Jackson C.M., Lin A.Y., Baumler C., Siegert E., Marx A., Vaishnaw A.K., Grodzicky T., Fleisher T.A., Lenardo M.J. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001, 98:194-200.
94. Hennino A., Berard M., Krammer P.H., Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J. Exp. Med. 2001, 193:447-458.
95. Montesinos-Rongen M., Van Roost D., Schaller C., Wiestler O.D., Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004, 103:1869-1875.
96. Muschen M., Rajewsky K., Kronke M., Kuppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 2002, 23:75-80.
97. Peter M.E., Legembre P., Barnhart B.C. Does CD95 have tumor promoting activities?. Biochim. Biophys. Acta 2005, 1755:25-36.
98. Legembre P., Barnhart B.C., Peter M.E. The relevance of NF-kappaB for CD95 signaling in tumor cells. Cell Cycle 2004, 3:1235-1239.
99. Legembre P., Barnhart B.C., Zheng L., Vijayan S., Straus S.E., Puck J., Dale J.K., Lenardo M., Peter M.E. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep. 2004, 5:1084-1089.
100. Barnhart B.C., Legembre P., Pietras E., Bubici C., Franzoso G., Peter M.E. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004, 23:3175-3185.
101. Kimura M., Matsuzawa A. Autoimmunity in mice bearing lprcg: a novel mutant gene. Int. Rev. Immunol. 1994, 11:193-210.
102. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
103. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
104. Adachi M., Watanabe-Fukunaga R., Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1756-1760.
105. Chu J.L., Drappa J., Parnassa A., Elkon K.B. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J. Exp. Med. 1993, 178:723-730.
106. Matsuzawa A., Moriyama T., Kaneko T., Tanaka M., Kimura M., Ikeda H., Katagiri T. A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse. J. Exp. Med. 1990, 171:519-531.
107. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30:180-192.
108. Heinzelmann F., Jendrossek V., Lauber K., Nowak K., Eldh T., Boras R., Handrick R., Henkel M., Martin C., Uhlig S., Kohler D., Eltzschig H.K., Wehrmann M., Budach W., Belka C. Irradiation-induced pneumonitis mediated by the CD95/CD95-ligand system. J. Natl. Cancer Inst. 2006, 98:1248-1251.
109. Kobayashi S., Hirano T., Kakinuma M., Uede T. Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice. Biochem. Biophys. Res. Commun. 1993, 191:617-624.
110. Wu J., Zhou T., He J., Mountz J.D. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J. Exp. Med. 1993, 178:461-468.
111. Martin D.A., Zheng L., Siegel R.M., Huang B., Fisher G.H., Wang J., Jackson C.E., Puck J.M., Dale J., Straus S.E., Peter M.E., Krammer P.H., Fesik S., Lenardo M.J. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4552-4557.
112. Orlinick J.R., Elkon K.B., Chao M.V. Separate domains of the human fas ligand dictate self-association and receptor binding. J. Biol. Chem. 1997, 272:32221-32229.
113. Chu J.L., Ramos P., Rosendorff A., Nikolic-Zugic J., Lacy E., Matsuzawa A., Elkon K.B. Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J. Exp. Med. 1995, 181:393-398.
114. Hadji A., Ceppi P., Murmann A.E., Brockway S., Pattanayak A., Bhinder B., Hau A., De Chant S., Parimi V., Kolesza P., Richards J., Chandel N., Djaballah H., Peter M.E. Death induced by CD95 or CD95 ligand elimination. Cell Rep. 2014, 7:208-222.
115. Lavrik I.N., Golks A., Riess D., Bentele M., Eils R., Krammer P.H. Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J. Biol. Chem. 2007, 282:13664-13671.
116. Kleber S., Sancho-Martinez I., Wiestler B., Beisel A., Gieffers C., Hill O., Thiemann M., Mueller W., Sykora J., Kuhn A., Schreglmann N., Letellier E., Zuliani C., Klussmann S., Teodorczyk M., Grone H.J., Ganten T.M., Sultmann H., Tuttenberg J., von Deimling A., Regnier-Vigouroux A., Herold-Mende C., Martin-Villalba A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
117. Malleter M., Tauzin S., Bessede A., Castellano R., Goubard A., Godey F., Leveque J., Jezequel P., Campion L., Campone M., Ducret T., Macgrogan G., Debure L., Collette Y., Vacher P., Legembre P. CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res. 2013, 73:6711-6721.
118. Grassme H., Jekle A., Riehle A., Schwarz H., Berger J., Sandhoff K., Kolesnick R., Gulbins E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 2001, 276:20589-20596.
119. Muppidi J.R., Siegel R.M. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat. Immunol. 2004, 5:182-189.
120. Stel A.J., Ten Cate B., Jacobs S., Kok J.W., Spierings D.C., Dondorff M., Helfrich W., Kluin-Nelemans H.C., de Leij L.F., Withoff S., Kroesen B.J. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J. Immunol. 2007, 178:2287-2295.
121. Delmas D., Rebe C., Lacour S., Filomenko R., Athias A., Gambert P., Cherkaoui-Malki M., Jannin B., Dubrez-Daloz L., Latruffe N., Solary E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem. 2003, 278:41482-41490.
122. Delmas D., Rebe C., Micheau O., Athias A., Gambert P., Grazide S., Laurent G., Latruffe N., Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004, 23:8979-8986.
123. Gajate C., Del Canto-Janez E., Acuna A.U., Amat-Guerri F., Geijo E., Santos-Beneit A.M., Veldman R.J., Mollinedo F. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J. Exp. Med. 2004, 200:353-365.
124. Gajate C., Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109:711-719.
125. Gajate C., Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. 2005, 280:11641-11647.
126. Lacour S., Hammann A., Grazide S., Lagadic-Gossmann D., Athias A., Sergent O., Laurent G., Gambert P., Solary E., Dimanche-Boitrel M.T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 2004, 64:3593-3598.
127. Anathy V., Aesif S.W., Guala A.S., Havermans M., Reynaert N.L., Ho Y.S., Budd R.C., Janssen-Heininger Y.M. Redox amplification of apoptosis by caspase-dependent cleavage of glutaredoxin 1 and S-glutathionylation of Fas. J. Cell Biol. 2009, 184:241-252.
128. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B.C., et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 1992, 267:10709-10715.
129. Grassme H., Cremesti A., Kolesnick R., Gulbins E. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 2003, 22:5457-5470.
130. Chen C.A., Wang T.Y., Varadharaj S., Reyes L.A., Hemann C., Talukder M.A., Chen Y.R., Druhan L.J., Zweier J.L. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468:1115-1118.
131. Leon-Bollotte L., Subramaniam S., Cauvard O., Plenchette-Colas S., Paul C., Godard C., Martinez-Ruiz A., Legembre P., Jeannin J.F., Bettaieb A. S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells. Gastroenterology 2011, 140:2009-2018. (2018 e2001-2004).
132. Chakrabandhu K., Herincs Z., Huault S., Dost B., Peng L., Conchonaud F., Marguet D., He H.T., Hueber A.O. Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 2007, 26:209-220.
133. Feig C., Tchikov V., Schutze S., Peter M.E. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 2007, 26:221-231.
134. Gradl G., Grandison P., Lindridge E., Wang Y., Watson J., Rudert F. The CD95 (Fas/APO-1) receptor is phosphorylated in vitro and in vivo and constitutively associates with several cellular proteins. Apoptosis 1996, 1:131-140.
135. Daigle I., Yousefi S., Colonna M., Green D.R., Simon H.U. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat. Med. 2002, 8:61-67.
136. Su X., Zhou T., Wang Z., Yang P., Jope R.S., Mountz J.D. Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 1995, 2:353-362.
137. Ohno H., Stewart J., Fournier M.C., Bosshart H., Rhee I., Miyatake S., Saito T., Gallusser A., Kirchhausen T., Bonifacino J.S. Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science 1995, 269:1872-1875.
138. Lee K.H., Feig C., Tchikov V., Schickel R., Hallas C., Schutze S., Peter M.E., Chan A.C. The role of receptor internalization in CD95 signaling. EMBO J. 2006, 25:1009-1023.
139. Atkinson E.A., Ostergaard H., Kane K., Pinkoski M.J., Caputo A., Olszowy M.W., Bleackley R.C. A physical interaction between the cell death protein Fas and the tyrosine kinase p59fynT. J. Biol. Chem. 1996, 271:5968-5971.
140. Wang J., Koizumi T., Watanabe T. Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J. Exp. Med. 1996, 184:831-838.
141. Khadra N., Bresson-Bepoldin L., Penna A., Chaigne-Delalande B., Segui B., Levade T., Vacher A.M., Reiffers J., Ducret T., Moreau J.F., Cahalan M.D., Vacher P., Legembre P. CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) beta2, and prevents death-inducing signaling complex formation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19072-19077.
142. Penna A., Khadra N., Tauzin S., Vacher P., Legembre P. The CD95 signaling pathway: to not die and fly. Commun. Integr. Biol. 2012, 5:190-192.
143. Stanger B.Z., Leder P., Lee T.H., Kim E., Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995, 81:513-523.
144. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T.J., Moskowitz M.A., Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 2005, 1:112-119.
145. Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X., Abbott D., Cuny G.D., Yuan C., Wagner G., Hedrick S.M., Gerber S.A., Lugovskoy A., Yuan J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 2008, 4:313-321.
146. Lee E.W., Seo J., Jeong M., Lee S., Song J. The roles of FADD in extrinsic apoptosis and necroptosis. BMB Rep. 2012, 45:496-508.
147. Lin Y., Devin A., Rodriguez Y., Liu Z.G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999, 13:2514-2526.
148. Feng S., Yang Y., Mei Y., Ma L., Zhu D.E., Hoti N., Castanares M., Wu M. Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell. Signal. 2007, 19:2056-2067.
149. O'Donnell M.A., Perez-Jimenez E., Oberst A., Ng A., Massoumi R., Xavier R., Green D.R., Ting A.T. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 2011, 13:1437-1442.
150. Peter M.E. Programmed cell death: apoptosis meets necrosis. Nature 2011, 471:310-312.
151. Montel A.H., Bochan M.R., Hobbs J.A., Lynch D.H., Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immunol. 1995, 166:236-246.
152. Saas P., Walker P.R., Hahne M., Quiquerez A.L., Schnuriger V., Perrin G., French L., Van Meir E.G., de Tribolet N., Tschopp J., Dietrich P.Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J. Clin. Invest. 1997, 99:1173-1178.
153. Stuart P.M., Griffith T.S., Usui N., Pepose J., Yu X., Ferguson T.A. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 1997, 99:396-402.
154. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366.
155. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996, 184:1075-1082.
156. Allison J., Georgiou H.M., Strasser A., Vaux D.L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3943-3947.
157. Kang S.M., Schneider D.B., Lin Z., Hanahan D., Dichek D.A., Stock P.G., Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 1997, 3:738-743.
158. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998, 282:1714-1717.
159. Bui J.D., Schreiber R.D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr. Opin. Immunol. 2007, 19:203-208.
160. Beneteau M., Daburon S., Moreau J.F., Taupin J.L., Legembre P. Dominant-negative Fas mutation is reversed by down-expression of c-FLIP. Cancer Res. 2007, 67:108-115.
161. Chen L., Park S.M., Tumanov A.V., Hau A., Sawada K., Feig C., Turner J.R., Fu Y.X., Romero I.L., Lengyel E., Peter M.E. CD95 promotes tumour growth. Nature 2010, 465:492-496.
162. Matsuno H., Yudoh K., Watanabe Y., Nakazawa F., Aono H., Kimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J. Rheumatol. 2001, 28:22-28.
163. Vargo-Gogola T., Crawford H.C., Fingleton B., Matrisian L.M. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys. 2002, 408:155-161.
164. Kiaei M., Kipiani K., Calingasan N.Y., Wille E., Chen J., Heissig B., Rafii S., Lorenzl S., Beal M.F. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2007, 205:74-81.
165. Kirkin V., Cahuzac N., Guardiola-Serrano F., Huault S., Luckerath K., Friedmann E., Novac N., Wels W.S., Martoglio B., Hueber A.O., Zornig M. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ. 2007, 14:1678-1687.
166. Schulte M., Reiss K., Lettau M., Maretzky T., Ludwig A., Hartmann D., de Strooper B., Janssen O., Saftig P. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007, 14:1040-1049.
167. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., Tinel A., Deperthes D., Calderara S., Schulthess T., Engel J., Schneider P., Tschopp J. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 2003, 23:1428-1440.
168. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998, 187:1205-1213.
169. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997, 186:2045-2050.
170. Cursi S., Rufini A., Stagni V., Condo I., Matafora V., Bachi A., Bonifazi A.P., Coppola L., Superti-Furga G., Testi R., Barila D. Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006, 25:1895-1905.
171. Senft J., Helfer B., Frisch S.M. Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res. 2007, 67:11505-11509.
172. Steller E.J., Borel Rinkes I.H., Kranenburg O. How CD95 stimulates invasion. Cell Cycle 2011, 10:3857-3862.
173. Steller E.J., Ritsma L., Raats D.A., Hoogwater F.J., Emmink B.L., Govaert K.M., Laoukili J., Rinkes I.H., van Rheenen J., Kranenburg O. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep. 2011, 12:931-937.
174. Bivona T.G., Hieronymus H., Parker J., Chang K., Taron M., Rosell R., Moonsamy P., Dahlman K., Miller V.A., Costa C., Hannon G., Sawyers C.L. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
175. Bellone G., Smirne C., Carbone A., Mareschi K., Dughera L., Farina E.C., Alabiso O., Valente G., Emanuelli G., Rodeck U. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clin. Cancer Res. 2000, 6:2448-2455.
176. Malleter M., Tauzin S., Bessede A., Castellano R., Goubard A., Godey F., Leveque J., Jezequel P., Campion L., Campone M., Ducret T., Macgrogan G., Debure L., Collette Y., Vacher P., Legembre P. CD95L cell surface cleavage triggers a pro-metastatic signaling pathway in triple negative breast cancer. Cancer Res. 2013, 73:6711-6721.
177. Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A.H., Nagata S. Fas ligand in human serum. Nat. Med. 1996, 2:317-322.
178. Hashimoto H., Tanaka M., Suda T., Tomita T., Hayashida K., Takeuchi E., Kaneko M., Takano H., Nagata S., Ochi T. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1998, 41:657-662.
179. Das H., Imoto S., Murayama T., Kajimoto K., Sugimoto T., Isobe T., Nakagawa T., Nishimura R., Koizumi T. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br. J. Haematol. 1999, 104:795-800.
180. Kanda Y., Tanaka Y., Shirakawa K., Yatomi T., Nakamura N., Kami M., Saito T., Izutsu K., Asai T., Yuji K., Ogawa S., Honda H., Mitani K., Chiba S., Yazaki Y., Hirai H. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 1998, 22:751-754.
181. Tomokuni A., Otsuki T., Isozaki Y., Kita S., Ueki H., Kusaka M., Kishimoto T., Ueki A. Serum levels of soluble Fas ligand in patients with silicosis. Clin. Exp. Immunol. 1999, 118:441-444.
182. Herrero R., Kajikawa O., Matute-Bello G., Wang Y., Hagimoto N., Mongovin S., Wong V., Park D.R., Brot N., Heinecke J.W., Rosen H., Goodman R.B., Fu X., Martin T.R. The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region. J. Clin. Invest. 2011, 121:1174-1190.
183. Alonso R., Mazzeo C., Rodriguez M.C., Marsh M., Fraile-Ramos A., Calvo V., Avila-Flores A., Merida I., Izquierdo M. Diacylglycerol kinase alpha regulates the formation and polarisation of mature multivesicular bodies involved in the secretion of Fas ligand-containing exosomes in T lymphocytes. Cell Death Differ. 2011, 18:1161-1173.
184. Bianco N.R., Kim S.H., Morelli A.E., Robbins P.D. Modulation of the immune response using dendritic cell-derived exosomes. Methods Mol. Biol. 2007, 380:443-455.
185. Abusamra A.J., Zhong Z., Zheng X., Li M., Ichim T.E., Chin J.L., Min W.P. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol. Dis. 2005, 35:169-173.
186. Schneider P., Bodmer J.L., Holler N., Mattmann C., Scuderi P., Terskikh A., Peitsch M.C., Tschopp J. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 1997, 272:18827-18833.